MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q3
hinzugefügt 13.11.2023
Orchard Therapeutics plc Betriebsaufwand 2011-2026 | ORTX
Betriebsaufwand Jährlich Orchard Therapeutics plc
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 159 M | 175 M | 237 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 237 M | 159 M | 190 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.55 | -0.42 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
79.7 M | $ 3.24 | 3.35 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
334 M | $ 4.14 | -1.9 % | $ 105 M | Schweiz |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.82 | 4.22 % | $ 4.47 M | China |
 |
argenx SE
ARGX
|
2.27 B | $ 714.55 | 1.6 % | $ 25 B |  Niderland |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 231.26 | 0.1 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.4 | -5.82 % | $ 8.18 B |  Australia |
 |
Atea Pharmaceuticals
AVIR
|
181 M | $ 6.09 | 0.66 % | $ 496 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 6.6 | -0.45 % | $ 181 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
BioCardia
BCDA
|
15.7 M | $ 1.37 | 7.87 % | $ 29 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
105 M | $ 11.29 | -2.5 % | $ 1.01 B | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 14.61 | 1.71 % | $ 214 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
BioNTech SE
BNTX
|
512 M | $ 92.9 | 2.61 % | $ 27.2 B | Germany |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.64 | - | $ 16.6 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
14.9 M | $ 2.36 | -3.67 % | $ 902 K | USA |
 |
CorMedix
CRMD
|
126 M | $ 6.57 | 0.46 % | $ 473 K | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.24 | 2.36 % | $ 1.33 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.5 | -0.99 % | $ 383 M | Britain |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |